Theorem Clinical Research

AstraZeneca

Amgen joins NCI to accelerate development of personalized cancer treatments

Tuesday, June 17, 2014 10:26 AM

Amgen will collaborate with the National Cancer Institute (NCI), part of the NIH, and other public and private sector partners, on the Lung Master Protocol (Lung-MAP), a new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol.

More... »


AstraZeneca in-licenses Synairgen's SNG001 for asthma in $232M deal

Thursday, June 12, 2014 01:38 PM

AstraZeneca has inked a global license agreement with Synairgen, a U.K. company specializing in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. SNG001 supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections.

More... »


Ventana, MedImmune collaborate for immunotherapy clinical trials

Thursday, June 5, 2014 10:30 AM

Ventana Medical Systems, a member of the Roche Group, and MedImmune, the global biologics R&D arm of AstraZeneca, are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that only will enroll patients who express PD-L1 as determined by the VENTANA assay.

More... »

Premier Research names Martin Nicklasson to board of directors

Friday, May 30, 2014 01:10 PM

CRO Premier Research has appointed Martin Nicklasson, Ph.D., to its board of directors.

More... »

Discovery Labs adds to scientific leadership team

Friday, May 23, 2014 12:23 PM

Discovery Laboratories, a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, has strengthened its scientific leadership. Effective immediately, Steve Simonson, M.D., M.H.S., has joined the company as vice president, Clinical Development, and Lawrence Weinstein has joined as vice president, Medical Device Development.

More... »

Human Longevity hires for clinical, regulatory/scientific and informatics

Thursday, May 22, 2014 10:43 AM

Human Longevity (HLI), a genomics and cell therapy-based diagnostic and therapeutic company, has announced three senior appointments to help build the company's business and technology platforms.

More... »

AstraZeneca rejects Pfizer’s “final” acquisition offer

Monday, May 19, 2014 12:02 PM

Barely nine hours after Pfizer made its fourth and “final” takeover offer, raising it to $118 billion, AstraZeneca rejected it today, ending the U.S. pharma giant’s plan to create the world’s largest biopharmaceutical company.

More... »

AstraZeneca, MRC Laboratory of Molecular Biology to launch joint research fund

Friday, May 16, 2014 12:47 PM

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology (MRC LMB) to fund a range of preclinical research projects aimed at better understanding the biology of disease.

More... »

Ligand, Omthera ink agreement for dyslipidemia

Thursday, May 15, 2014 01:21 PM

Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals, a wholly-owned subsidiary of AstraZeneca, for the development of products to treat dyslipidemia, including hypertriglyceridemia.

More... »

Incyte, MedImmune collaborate on immuno-oncology clinical trial

Wednesday, May 14, 2014 01:30 PM

Incyte, a Wilmington, Del.-based biopharmaceutical company, and MedImmune, the global biologics R&D arm of AstraZeneca, have entered into a clinical study collaboration. The phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs